doxorubicin, used in pediatric chemotherapy regimens, has cardiotoxic effects. dexrazoxane is co-administrated with doxorubicin to prevent its cardiotoxicity. here we have explored some alternative food or drugs to be used in absence of dexrazoxane since it’s not readily available in iran at this time. keywords: pediatric, chemotherapy, doxorubicin, cardiotoxicity, dexrazoxane, iran.

Chemotherapy-induced cardiotoxicity is a serious complication that poses a serious threat to life and limits the clinical use of various chemotherapeutic agents, particularly the anthracyclines. Understanding molecular mechanisms of chemotherapy-induced cardiotoxicity is a key to effective preventive strategies and improved chemotherapy regimen. Although no reliable and effective preventive tre...

OBJECTIVES Case reports of capecitabine cardiotoxicity resemble those seen with intravenous 5-fluorouracil (5-FU) with chest pain as the predominant manifestation, but few studies of capecitabine cardiotoxicity are available. We aimed to determine the incidence of symptomatic cardiotoxicity from capecitabine in patients with breast cancer and to identify risk factors. METHODS We reviewed medi...

PURPOSE In the present study, we investigated the incidence of cardiotoxicity within 5 years of trastuzumab treatment and evaluated potential risk factors in clinical practice. METHODS The study cohort included 415 patients diagnosed with early breast cancer (EBC). Cardiotoxicity incidence was evaluated in patients receiving trastuzumab and those who did not. Multivariate Cox proportional haz...

Cardiotoxicity is a well-known potential side effect of several chemotherapeutic agent. Patients undergoing chemotherapy highly exposed to cardiac complications. Chemotherapeutic agents like anthracycliines, cyclophosphamide and signaling inhibitors like human monoclonal antibodies and tyrosine kinase inhibitors worsen cardiovascular system. A number of cardiovascular events occur during cardio...

Anthracyclines, especially doxorubicin and daunorubicin, are the drugs of first choice in the treatment of patients with hematologic malignancies, soft-tissue sarcomas, and solid tumors. Unfortunately, the use of anthracyclines is limited by their dose-dependent and cumulative cardiotoxicity. The molecular mechanism responsible for anthracycline-induced cardiotoxicity remains poorly understood,...

Citation: Leslie C Sharkey and Beshay N Zordoky. “Sexual Dimorphism of Doxorubicin-Induced Cardiotoxicity”. EC Pharmacology and Toxicology 1.S1 (2015): S4-S6. Doxorubicin is a potent chemotherapeutic agent widely used to treat both hematologic malignancies and solid tumours in paediatric and adult cancer patients. Unfortunately, the clinical utility of this effective agent is limited by dose-de...

Doxorubicin is a widely used chemotherapeutic agents and is now part of standard therapeutic regimens for a variety of cancers (eg, hematopoietic malignancies and advanced solid tumors of the breast, ovary, thyroid, and bone). However, a potentially lethal and dose-dependent cardiotoxicity that appears within a short time after treatment limits the usage of doxorubicin in cancer patients. Altho...

Background. Right ventricular (RV) dysfunction during cancer therapy related cardiotoxicity and its prognostic implications have not been examined. Aim. We sought to determine the incidence and prognostic value of RV dysfunction at time of LV defined cardiotoxicity. Methods. We retrospectively identified 30 HER2+ female patients with breast cancer treated with trastuzumab (± anthracycline) who ...

Background: The use of doxorubicin in chemotherapy has been associated with cardiotoxicity and heart failure. Physical exercise produces favorable morphofunctional adaptations the cardiovascular system may reverse cardiac dysfunction patients undergoing chemotherapy. Objective: To assess effects physical training on myocardial structure, function, tolerance Wistar rats initiated after onset car...